Defining Molecular Targets to Prevent Alzheimer Disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
An explosion of new techniques to explore DNA and protein biology during the last 2 decades has illuminated one of the most enigmatic and intractable subjects in biomedicine—neurodegeneration. Eponymic diseases of the nervous system that were untilrecentlycharacterizedbymechanisticignoranceandtherapeuticnihilismarefalling steadily to the power of molecular genetics, cell biology, biochemistry, and animal modeling. Alzheimer, Huntington, Creutzfeld-Jacob, and Parkinson diseases, as well as amyotrophic lateral sclerosis, spinocerebellar atrophies, frontotemporal dementia, and other previously obscure diseases, have all yielded rapid progress in the deciphering of their biochemical pathology and genetic underpinnings. This sea change in our understanding of a group of incurable diseases that confer enormous personal and societal burdens has brought us to the verge of rationally designed therapies and, in some cases, into actual human trials. Perhaps the foremost example, both in terms of its impact on society and how far we have moved toward clinical application, is that of Alzheimer disease (AD). Thismostcommonofthelate-lifedementias is rising in prevalence with the aging ofpopulationsindevelopedcountriesand may now affect 20 to 30 million people worldwide. I will review the classic neuropathological lesions of AD that, despite some doubts along the way, turned out to provide a road map to the etiology and pathogenesis of the disease. Then, I willdiscusshowelucidatingthegenotypeto-phenotype relationships of certain genetic alterations linked to familial forms ofADhaspinpointedmoleculartargetsfor treatment and prevention, some of which are now being addressed in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“In accord, the first AD-causing gene to be identified was APP, in which dominantly inherited mutations lead to an early and aggressive form of the disease.(5) As many as 20 APP missense mutations are now known, and they all cluster at or near the sites in the precursor that are cleaved by the -, - or -secretases.”
BackgroundThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“In particular, the isolation and partial sequencing of the amyloid -protein (A ) by Glenner and Wong,(1) followed by the recognition that amyloid plaques (but not neurofibrillary tangles) were composed of the same protein, led to the cloning of the -amyloid precursor protein (APP) and the localization of its gene to h…”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“In cell culture, transgenic mouse models, and the sera and brains of affected patients, it has been shown that PS1 and PS2 missense mutations increase the production of A 42, the highly selfaggregating 42-residue form of A , often at the expense of the more commonly produced 40-residue form.(11) The mutations do so be…”
BackgroundSelf-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Indeed, studies in double transgenic mice suggest that the presence of A -elevating APP mutations augments the formation of tau deposits in neurons, rather than the converse.(13) The precise way in which A accumulation induces a cascade of neuronal metabolic changes that includes the hyperphosphorylation of wild-type…”
BackgroundA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“Intriguingly, there is evidence that certain nonsteroidal anti-inflammatory drugs such as ibuprofen may subtly modulate -secretase cleavage to lower A 42 production without impairing A 40 production and Notch cleavage.(15) Derivatives of certain anti-inflammatory drugs that can no longer inhibit cyclooxygenase activit…”
BackgroundHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“Subsequently, elegant experiments in apoE knockout and transgenic mouse models showed that the presence of the apoE4 protein markedly increases the amount of fibrillar A deposits in the brain compared with the effects of the apoE3 protein.(8) The next 2 AD genes discovered were presenilin (PS) 1 and PS2.”
Background
Cited by
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
“Some biomarkers directly reflect the pathology of AD by providing evidence of the presence of key proteins deposited in the brain during the course of AD, such as the betaamyloid protein (Ab) and tau [14].”
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Overview and Findings from the Rush Memory and Aging Project
A. Bennett, D., A. Schneider, J., S. Buchman, A., L. Barnes, L., A. Boyle, P., & S. Wilson, R. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322663 · Cited by 862
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Metadata
- Authors
- Selkoe, D. J.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2005-02-01
- Volume
- 62
- Issue
- 2
- Pages
- 192
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2103126689
- Cited by
- 149
- References
- 9
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining Molecular Targets to Prevent Alzheimer Disease. https://app.cochat.ai/papers/10.1001/archneur.62.2.192
- The paper
- Selkoe, D. J. (2005). Defining Molecular Targets to Prevent Alzheimer Disease. Archives of Neurology. https://doi.org/10.1001/archneur.62.2.192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.